Essex Investment Management Co. LLC Trims Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Essex Investment Management Co. LLC trimmed its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNFree Report) by 15.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,159 shares of the biopharmaceutical company’s stock after selling 212 shares during the quarter. Essex Investment Management Co. LLC’s holdings in Regeneron Pharmaceuticals were worth $954,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of REGN. Sunbelt Securities Inc. purchased a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth about $25,000. Annis Gardner Whiting Capital Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the third quarter worth about $26,000. Sutton Wealth Advisors Inc. grew its stake in shares of Regeneron Pharmaceuticals by 38.2% during the third quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 13 shares during the last quarter. Benjamin F. Edwards & Company Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 1,933.3% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 61 shares of the biopharmaceutical company’s stock worth $44,000 after purchasing an additional 58 shares during the period. Finally, Milestone Investment Advisors LLC purchased a new stake in Regeneron Pharmaceuticals in the third quarter valued at approximately $54,000. Hedge funds and other institutional investors own 84.15% of the company’s stock.

Insider Activity

In other news, Director Bonnie L. Bassler sold 827 shares of the firm’s stock in a transaction that occurred on Tuesday, January 30th. The stock was sold at an average price of $959.00, for a total value of $793,093.00. Following the transaction, the director now owns 1,382 shares in the company, valued at $1,325,338. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $817.30, for a total value of $81,730.00. Following the completion of the sale, the director now owns 18,447 shares of the company’s stock, valued at $15,076,733.10. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Bonnie L. Bassler sold 827 shares of the stock in a transaction that occurred on Tuesday, January 30th. The shares were sold at an average price of $959.00, for a total value of $793,093.00. Following the completion of the sale, the director now directly owns 1,382 shares of the company’s stock, valued at approximately $1,325,338. The disclosure for this sale can be found here. Insiders have sold a total of 11,911 shares of company stock worth $10,781,770 over the last quarter. 8.83% of the stock is currently owned by corporate insiders.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $953.42 on Monday. The company has a market cap of $103.88 billion, a PE ratio of 27.44, a price-to-earnings-growth ratio of 2.76 and a beta of 0.11. The stock’s 50 day simple moving average is $900.23 and its 200-day simple moving average is $842.29. Regeneron Pharmaceuticals, Inc. has a 1-year low of $684.80 and a 1-year high of $973.99. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.69 and a quick ratio of 4.94.

Regeneron Pharmaceuticals (NASDAQ:REGNGet Free Report) last released its earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, beating the consensus estimate of $10.73 by $1.13. The business had revenue of $3.43 billion for the quarter, compared to the consensus estimate of $3.29 billion. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. The business’s quarterly revenue was up .6% compared to the same quarter last year. During the same quarter last year, the business posted $10.96 earnings per share. As a group, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 38.53 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently commented on REGN. BMO Capital Markets upped their price objective on shares of Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the company an “outperform” rating in a report on Monday, February 5th. Truist Financial reaffirmed a “buy” rating and set a $1,045.00 price target on shares of Regeneron Pharmaceuticals in a research report on Monday, December 18th. Jefferies Financial Group boosted their price objective on Regeneron Pharmaceuticals from $935.00 to $937.00 and gave the company a “buy” rating in a report on Tuesday, November 28th. Royal Bank of Canada upped their target price on Regeneron Pharmaceuticals from $1,076.00 to $1,110.00 and gave the stock an “outperform” rating in a research note on Monday, February 5th. Finally, Barclays upped their target price on Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 23rd. One investment analyst has rated the stock with a sell rating, five have given a hold rating and nineteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $939.05.

Check Out Our Latest Research Report on REGN

Regeneron Pharmaceuticals Company Profile

(Free Report)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

See Also

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNFree Report).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.